Germany’s benefit committee uses a European assessment report for the first time
The report on tovorafenib does not conclude whether the drug has an added benefit. The committee could not quantify any added benefit.
On 5 November 2026, Germany’s Federal Joint Committee used a European joint clinical assessment report in a national decision for the first time. These reports describe study data. They do not conclude whether a drug has an added benefit. In Germany, the committee still decides whether an added benefit exists and how large it is.
The first case is tovorafenib, a medicine for a low-grade malignant glioma, especially in children and adolescents. The European Commission granted a conditional authorisation in April 2026. The medicine has been available in Germany since May 2026, and statutory health insurance covers the cost. Because it is a medicine for a rare disease, an added benefit is legally assumed until sales reach €30 million. The committee then assesses only the extent, and it could not quantify that extent. The evidence included a study without a comparison group.
The decision is the basis for price talks between insurers and the manufacturer. It is not a recommendation for an individual person. Joint European assessments have applied since January 2025 to new cancer medicines and certain advanced therapies. From 2030 they are to cover all newly authorised medicines.
Sources
- Europäische Nutzenbewertung von Arzneimitteln: G-BA bezieht ersten JCA-Bericht in nationales Bewertungsverfahren ein (opens in a new tab) · Gemeinsamer Bundesausschuss (G-BA) · Accessed on